WHOCC
Postal address:
Norwegian Institute of Public Health
WHO Collaborating Centre for Drug Statistics Methodology
Postboks 222 Skøyen
0213 Oslo
Norway

Visiting/delivery address:
Myrens verksted 6H
0473 Oslo
Norway

Tel:  +47 21 07 81 60
E-mail:
 
Copyright/Disclaimer

New DDDs

ATC codeATC level nameNew DDDUnitAdm.routeDeadline for objection to temporary codesImplementation in ATC/DDD index
R03DX12depomokimab0.55mgP20.08.20262027
N07XX21eplontersen1.5mgP20.08.20262027
N05CJ03daridorexant50mgO20.08.20262027
N04BA01levodopa0.198gInhal.powder20.08.20262027
N02AF03levorphanol6mgO20.08.20262027
N02AC56dipipanone and cyclizine40 2)mgO20.08.20262027
M09AX14givinostat0.1gO20.08.20262027
L04AJ08iptacopan0.4gO20.08.20262027
L04AG14ublituximab2.7mgP20.08.20262027
L04AG10inebilizumab1.64mgP20.08.20262027
L04AC29xeligekimab7.14mgP20.08.20262027
L01EX28repotrectinib0.32gO20.08.20262027
L01EX11quizartinib53mgO20.08.20262027
L01EB09lazertinib0.24gO20.08.20262027
J01DE51cefepime and beta-lactamase inhibitor6 1)gP20.08.20262027
H02AB18vamorolone0.24gO20.08.20262027
D11AH12nemolizumab0.54mgP20.08.20262027
C10AX17evinacumab37.5mgP20.08.20262027
C08CA17levamlodipine2.5mgO20.08.20262027
C01EB25acoramidis1.42gO20.08.20262027
B06AC09donidalorsen2.86mgP20.08.20262027
B06AC07garadacimab6.67mgP20.08.20262027
A10BJ08efsubaglutide alfa0.29mgP20.08.20262027
A05AX06elafibranor80mgO20.08.20262027
1) refers to cefepime
2) refers to dipipanone

Last updated: 2026-07-17